April 6, 2018 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive CBD innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has signed a Letter of Intent (“LOI”) with Agrima Botanicals Corp. (“Agrima”), a Canadian Licensed Producer, to import 99.5%+ pure, bioactive pharma-grade cannabidiol (‘CBD’) isolate into Canada from Isodiol’s GMP-certified production facility in the United Kingdom.
Agrima intends to import up to 5,000 g of CBD isolate per month for the purposes of R&D, product formulation and production of pharma-grade derivative products.
Marcos Agramont, CEO of Isodiol, stated, “Isodiol will continue to focus on providing the highest quality, pharma grade, raw material to its select partners who are formulating market leading cannabidiol products. The team at Agrima Botanicals is known for their focus on R&D and we are looking forward to our work together in additional product development opportunities, as well as potential clinical trials.”
“We are pleased to establish this new relationship with one of the leading CBD companies in the industry” explained Reid Parr, COO of Agrima. “This agreement will provide us with mutual opportunities to advance our respective research and development initiatives, as well as pave the way for additional collaboration to develop highest quality products based on a rigorous scientific approach.”
Upon successful initial import and product testing, Agrima and Isodiol intend to execute a Definitive Supply Agreement, which expects to expand the scope of the collaboration to additional products, in addition to the supply of raw isolate.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
COMPANY MEDIA :
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.